CTI BIOPHARMA
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.ctibiopharma.com/
Clinical Trials
38
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
- Conditions
- Drug Interactions
- Interventions
- Drug: CYP450 Cocktail and Transporter Substrates with PacritinibDrug: Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with PacritinibDrug: Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 60
- Registration Number
- NCT05657613
- Locations
- 🇺🇸
Site 1, Austin, Texas, United States
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
- Conditions
- Hepatic Impairment
- Interventions
- Drug: oral dose of 200 mg pacritinib twice daily (BID)
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 29
- Registration Number
- NCT05552183
- Locations
- 🇺🇸
Site 2, Orlando, Florida, United States
🇺🇸Site 1, San Antonio, Texas, United States
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
- Conditions
- Primary MyelofibrosisPost- Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 165
- Registration Number
- NCT04884191
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 200
- Registration Number
- NCT04404361
- Locations
- 🇺🇸
St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States
🇺🇸Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 28
- Registration Number
- NCT02823171
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
X4 Pharmaceuticals Secures $60 Million Financing and Installs New Leadership Team
X4 Pharmaceuticals announced a $60 million private placement financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates to support continued development of mavorixafor.
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.